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Abstract: In ethylenediaminetetraacetic acid (EDTA)-dependent
pseudothrombocytopenia (PTCP), automated platelet counts are lower
than actual counts because of EDTA-induced aggregation. Factors
contributing to the incidence of EDTA-PTCP are unknown, and no
study has assessed the prognosis of EDTA-PTCP patients.
This retrospective study assessed characteristics in EDTA-PTCP
patients and matched controls to determine differences in prognosis.
A retrospective case–control study was designed. From the Uni-
versity of Tokyo Hospital database, we identified patients diagnosed
with EDTA-PTCP between 2009 and 2012, and performed 1:2 case:-
control matching for age and sex. A control group of sex- and age-
matched patients was selected at random from the same database. We
investigated differences in the frequency of complications, medication
history, and blood transfusion history between the groups at the time of
blood collection. Prognosis was evaluated using multivariate Cox
regression analysis adjusting for age, sex, autoimmune disease, liver
disease, and malignant tumor.
We identified 104 EDTA-PTCP patients and 208 matched controls.
The median age was 69.0 years (interquartile range: 54–76), with men
comprising 51%. EDTA-PTCP patients had a higher frequency of
malignant tumor and a lower frequency of hypertension and diabetes
than controls. After adjustment for background factors, prognosis of
EDTA-PTCP patients was significantly poorer than controls (hazard
ratio, 11.8; 95% confidence intervals, 2.62–53.54). In conclusion,
EDTA-PTCP patients had higher mortality, and EDTA-PTCP may
need to be recognized as an indicator of worse prognosis.
(Medicine 94(15):e674)
Abbreviations: EDTA = ethylenediaminetetraacetic acid, EDTA-
PTCA = ethylenediaminetetraacetic acid-dependent pseudo-
thrombocytopenia.
INTRODUCTION
E thylenediaminetetraacetic acid (EDTA)-dependent pseudo-thrombocytopenia (PTCP) is a rare phenomenon whereby
platelets aggregate in reaction to the anti-coagulant EDTA-2K
contained in blood collection tubes. Consequently, platelet
counts measured with an automated blood cell counter appear
lower than they actually are.1 Physicians are seldom aware that
a normal platelet count can be obtained simply by changing the
collection method in a laboratory,2 such as using kanamycin or
sodium citrate, to avoid platelet agglutination.3,4
EDTA-PTCP has an incidence of about 0.1% in the general
population and up to 0.21% in hospitalized patients.4–7 In
addition, EDTA-PTCP is clinically recognized as a mere in
vitro phenomenon, with no impact on the prognosis. However, a
previous report suggested that EDTA-PTCP occurs more fre-
quently in severely ill patients with autoimmune, neoplastic,
atherosclerosis-related, and liver diseases.8 Meanwhile, other
studies reported no association with age, sex, burns, trauma,
sepsis, human immunodeficiency virus, rubella, cytomegalo-
virus, autoimmune disorders, malignancy, cardiac surgery, or
medication.2,9 Therefore, whether EDTA-PTCP increases the
risk of developing pathologies remains controversial. Further-
more, no study has examined the prognosis associated with
EDTA-PTCP.
Thus, we conducted a case–control study with a group of
EDTA-PTCP patients to compare the proportions of comorbid-
ities, oral medication histories, and blood transfusion histories
based on the presence of EDTA-PTCP and to examine whether
EDTA-PTCP patients have a poorer prognosis than those with-
out EDTA-PTCP.
METHODS
Study Design and Setting
This retrospective case–control study was conducted at The
University of Tokyo Hospital between April 2009 and January
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2012 with follow-upuntil October 2013. This study was approved
by the Ethics Committee of the University of Tokyo Hospital.
Participants
From the medical database of our hospital, which includes
around 60 000 patients who underwent a blood test between April
2009 and January 2012, we identified 104 patients diagnosed
with EDTA-PTCP by a blood test. Factors contributing to the
incidence of EDTA-PTCP are unknown. Therefore, we only
performed 1:2 case:control matching for age and sex. A control
group of 208 sex-and age-matched (within 5 years) patients was
selected at random from the same database. The exclusion
parameters were age under 18, multiple comorbidities, or other
hematologic diseases related to blood clotting that could be
associated with similar comorbidities. Our facility routinely
examines a smear under a microscope if a patient’s platelet count
is under 100 000 cells/mL or decreases over 30% compared with
the previous count because visual evaluation of blood smears is
regarded as the gold standard for detection of EDTA-PTCP.10 A
diagnosis of EDTA-PTCP is made via confirmation of platelet
aggregation. Blood samples were subsequently collected in tubes
containing 20 mg/mL of kanamycin, as excess aminoglycoside
antibiotics such as kanamycin can prevent platelet agglutination
in blood samples from EDTA-PTCP patients. Furthermore, pla-
telet aggregates can even be dissociated by the addition of these
antibiotics within 30 min after blood withdrawal.3
Data Sources/Measurements
At the time of blood collection, the following data were
collected from patients’ medical records: patients’ age; sex;
comorbidities including hypertension, diabetes, autoimmune
disease, malignant tumor, liver disease, and heart disease;
medications including aspirin, other antiplatelet, warfarin,
steroids, anti-cancer drugs, Chinese herbal medicines, and
anti-convulsants; and blood transfusion history. Patients’ deaths
by the end of October 2013 were confirmed by medical record
or telephone survey (author NO). If a patient had died, the date
of death was also collected.
The primary outcome of the study was mortality. In
addition, we also examined factors contributing to the incidence
of EDTA-PTCP by comparing characteristics between patients
with and without EDTA-PTCP.
Statistical Methods
We examined differences in the frequency of compli-
cations, medication use, and history of blood transfusion
between the EDTA-PTCP and control groups. Categorical data
were compared with the x2 test. Univariate and multivariate Cox
regression analyses were then conducted to investigate the
association between EDTA-PTCP and mortality. Factors used
in the final model were age, sex, malignancy, autoimmune
disease, and liver disease. Previous studies have suggested that
these diseases were associated with EDTA-PTCP pathogen-
esis.2,8 The level of significance was defined as a P value<0.05.
All statistical analyses were performed using STATA Special
Edition version 13.1 (StataCorp, College Station, TX).
RESULTS
Participants
Table 1 illustrates patient demographics of 104 EDTA-
PTCP patients and 208 matched controls. The median age of the
patients was 69 years (interquartile range [IQR]: 54–76 years),
with the majority aged >60 years. Men accounted for 51%.
The median length of patient follow-up was 308 days (IQR
768–1562 days).
Descriptive Data
Tables 1 and 2 show comparisons of background con-
ditions between the cases and controls. The cases were less
likely to have hypertension (36% vs 48%, P¼ 0.044) and
diabetes mellitus (17% vs 39%, P¼ 0.001) than the controls.
On the other hand, the cases were more likely have malignancy
(44% vs 22%, P< 0.001).
There were no significant differences between the 2 groups
in frequency of heart disease, autoimmune disease, liver dis-
ease, history of blood transfusion, medication use, and type
of cancer.
Main Results
Table 3 shows the results of univariate and multivariate
Cox regression analyses. The loss-to-follow-up value was 1/208
TABLE 1. Patient Characteristics, Complications, and Drugs
Compared Between Patients With and Without EDTA-PTCP
EDTA-PTCP
(n¼ 104)
Control
(n¼ 208) P
Median (IQR) age, y 69.0 (54–76) 68.5 (54–76) 0.918
Age distribution, y
<18 1 2
18–29 3 6
30–39 6 12
40–49 11 22
50–59 14 28
60–69 19 38
70–79 38 76
>80 12 24
Sex (male, %) 53(51) 106(51) 1
Complications
Hypertension, % 37 (36) 99 (48) 0.044

Diabetes mellitus, % 18 (17) 82 (39) <0.001

Heart disease, % 11 (11) 39 (19) 0.064
Malignancy, % 46 (44) 45 (22) <0.001

Autoimmune
disease, %
26 (25) 37 (18) 0.135
Hepatic disease, % 29 (28) 41 (20) 0.103
Previous blood
transfusion, %
22 (21) 38 (18) 0.542
Drugs
Aspirin, % 19 (18) 58 (28) 0.113
Other antiplatelet
drug, %
10 (10) 34 (16) 0.141
Warfarin, % 19 (18) 47 (23) 0.493
Steroid, % 9 (8.7) 29 (14) 0.169
Anticancer drug, % 5 (4.8) 9 (4.3) 0.835
Chinese herbal
medicine, %
3 (2.9) 6 (2.9) 0.390
Anticonvulsant, % 2 (1.9) 13 (6.3) 0.091
EDTA-PTCP¼ ethylenediaminetetraacetic acid-dependent pseudo-
thrombocytopenia; IQR¼ interquartile range.
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(0.48%) in control and 4/104 (3.70%) in EDTA-PTCP patients.
In a univariate analysis, patients with EDTA-PTCP had a hazard
ratio of 17.0 (95% CI 3.89–74.36) for mortality, compared with
those without EDTA-PTCP. Male sex, malignancy, and hepatic
disease were also significantly associated with mortality.
In the multivariate analysis, the hazard ratio between
patients with and without EDTA-PTCP decreased to 11.8
(95% CI 2.62–53.54), but EDTA-PTCP was still significantly
associated with mortality (Table 3). Other conditions were not
significantly associated with mortality in the multivariate
analysis, whereas there was weak evidence of an association
between malignancy and death (hazard ratio 2.67; 95% CI
0.85–8.36).
DISCUSSION
This large case–control study revealed that EDTA-PTCP
patients had a higher frequency of malignancy as a comorbidity
and higher mortality than age- and sex-matched controls.
These findings are consistent with an earlier report indi-
cating that malignant tumor is a common comorbidity in
EDTA-PTCP patients.8 Furthermore, the data support a pre-
viously reported mechanism for the occurrence of EDTA-
PTCP. When antigens of EDTA-dependent anti-platelet anti-
bodies undergo cryptogenic exposure, antibodies against these
antigens are produced. These antigens subsequently bind to
platelets and cause agglutination in the presence of EDTA in
vitro.11 The likelihood of crypto-antigens in the blood, as well
as the production of EDTA-dependent anti-platelet antibodies,
may increase with malignant tumors, liver disease, or auto-
immune disease.12 Of these factors, we demonstrated that
malignant tumor increased the risk of EDTA-PTCP. Although
the clinical relevance of EDTA-dependent anti-platelet auto-
antibodies in vivo remains uncertain,13 EDTA-PTCP patients
may need further evaluation.
We demonstrated that EDTA-PTCP patients have a higher
mortality than do other patients, even after adjustment for age,
sex, malignant tumors, liver disease, and autoimmune disease.
We have previously discussed the possibility that EDTA-PTCP
can be a cause of eosinophilic disease in a patient with eosi-
nophilic pneumonia.12 Additionally, others have shown that
EDTA-dependent anti-platelet antibodies cause platelet aggre-
gation in the presence of substances contained in blood transfu-
sions such as citric acid.14–16 These in vivo studies have
suggested that EDTA-PTCP is a systemic condition affecting
the body through platelet stimulation. Therefore, EDTA-PTCP
should be recognized not only as a benign in vitro phenomenon,
but also as an indicator of a disease that affects patients’
outcomes.
Further studies are needed to determine the impact of the
location and stage of malignant tumors on EDTA-PTCP and to
assess whether EDTA-PTCP develops beyond a specific stage
of cancer.
LIMITATIONS
This study has certain limitations. First, this single-center
study cannot account for different blood collection practices
that would be reflected in a multi-center study. In fact, the
number of people with malignant tumors, autoimmune disease,
or liver disease might be higher than that in the general
population. In addition, this study was performed with a hospital
control match. Thus, the proportion of hypertension or diabetes
is higher than that in the general population. Second, by
definition, this retrospective study was limited to the parameters
available in medical records. Although we included important
measured confounders reported in previous studies, a Cox
regression analysis could not account for unmeasured confoun-
ders. In particular, we could not differentiate the affected organ,
TABLE 2. Types of Cancer
EDTA-PTCP
(n¼ 38)
Control
(n¼ 31) P
0.204
Liver cancer 11 6
Uterus cancer 1 3
Lung cancer 4 1
Colon cancer 3 1
Pharyngeal cancer 2 0
Pancreatic cancer 2 4
Blood cancer 6 3
Gastric cancer 3 3
Renal cancer 1 0
Breast cancer 4 1
Skin cancer 1 1
Eye cancer 0 1
Bladder cancer 0 3
Ovary cancer 0 1
Esophageal cancer 0 1
Prostatic cancer 0 2
EDTA-PTCP¼ ethylenediaminetetraacetic acid-dependent pseudo-
thrombocytopenia.
TABLE 3. Univariate and Multivariate Cox Regression Analyses for Mortality
Univariate Multivariate
Variable HR 95% CI P HR 95% CI P
EDTA-PTCP 17.00 3.89–74.36 <0.001 11.84 2.62–53.54 <0.001
Age 1.04 0.99–1.08 0.088 1.03 0.98–1.08 0.203
Sex 0.31 0.10–0.96 0.042 0.39 0.12–1.24 0.11
Malignancy 6.21 2.19–17.6 0.001 2.67 0.85–8.36 0.092
Autoimmune disease 1.11 0.36–3.43 0.85 1.37 0.43–4.38 0.6
Hepatic disease 3.79 1.46–9.82 0.006 1.73 0.60–5.01 0.314
HR¼ hazard ratio, CI¼ confidence interval, EDTA-PTCP¼ ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia.
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pathological type, and stage classification of malignancy, which
appeared to be residual confounding factors in the association
between EDTA-PTCP and mortality.
CONCLUSION
This study demonstrated that patients with EDTA-PTCP
have a significantly higher mortality rate than age- and sex-
matched patients without EDTA-PTCP.
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